A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Homozygous Familial Hypercholesterolemia

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Homozygous Familial Hypercholesterolemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 May 2018

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Registrational; Therapeutic Use
  • Acronyms ODYSSEY HoFH
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 02 May 2018 Planned End Date changed from 1 Apr 2019 to 18 Jun 2019.
    • 02 May 2018 Planned primary completion date changed from 1 Dec 2018 to 23 Jan 2019.
    • 08 Nov 2017 According to Regeneron Pharmaceuticals media release, this trial was initiated in the third quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top